RU2491921C1 - Method of treating mastitis in non-lactating cows - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. The method of treating mastitis in non-lactating cows involves administering an antimicrobial preparation presented by apramycin in a combination with xanthane gum in ratios, wt %: apramycin - 5.0-10.0; xanthane gum - 0.25-1.0; distilled water - up to 100 with the preparation introduced intracisternally after the last evening milking before going non-lactating in the amount of 10 ml in a single dose.

EFFECT: invention provides the higher clinical effectiveness and reduced material expenses.

1 tbl, 1 ex

Description

The invention relates to veterinary medicine, in particular for the treatment of mastitis in cows in the dry period.

Currently, for the treatment of mastitis in cows there is a wide range of methods using drugs of various forms, which include antibiotics, sulfonamides, nitrofurans, etc.).

Among the domestic drugs used to treat mastitis in cows, Dienomast is known - a complex preparation containing the antibiotic gentamicin sulfate (200 μg / g), dioxidine 1000 μg / g), beeswax and vaseline oil (Veterinary preparations of Russia. Reference book. M ., 2004, part 1 - S.461).

For the treatment of sick mastitis of cows in the dry period, a number of treatment methods are known using imported drugs, such as Orbenin EDC and Bayoklos DC, Ampiclox), they contain antibacterial drugs Cloxacilin and Ampicillin (V.A. Parikov, N.T. Klimov and other mastitis in cows (prevention and therapy) // J. Veterinary Medicine, 2000, No. 11, P.34-37), after these preparations, milk can be consumed no earlier than 120-252 hours, in addition, these drugs are more expensive than domestic ones 3-4 times.

As you know, such preparations containing antibiotics should be prescribed no more than 3-6 months, and reapplied only after a year, since the sensitivity of the drug to the microflora decreases.

Also known from the prior art are “Method for the treatment of acute lactational mastitis in cows,” RF patent No. 2396089, “Method for the treatment and prevention of mastitis in cows,” RF patent No. 2355401, “Method for the treatment of acute lactation mastitis in cows,” RF patent No. 2396089, in which the antibiotic Mastisan E in complex combination with the Khotenets zeolites of the Oryol region, which, being sorbents of free radicals, normalize free-radical oxidation due to sorption properties.

The objective of the research was to increase the therapeutic effect of treatment, accessibility and lower cost of the drug and expand the range of dosage forms for the treatment of mastitis in cows in the dry period.

The technical result consists in cheaper, safer use for the treatment of mastitis in cows in the dry period of a drug that is not difficult to manufacture with a high therapeutic effect.

The object is achieved by the method of treating mastitis in cows in the dry period with a medicinal product with the inclusion of an antibacterial agent, characterized in that apramycin in combination with xanthan gum is used as an antibacterial agent in ratios, wt.%: Apramycin - 5.0-10.0; xanthan gum - 0.25-1.0; distilled water - the rest is up to 100, and the drug is administered itcisternally after the last milking before being transferred to the dry group in the amount of 10 ml once.

To solve this problem, a solution of apramycin in combination with xanthon resin was used; distilled water was used as a diluent.

Apramycin is an aminoglycoside antibiotic (aminocyclitol). The drug has a wide spectrum of antimicrobial activity and is active against gram-negative and some gram-positive bacteria. Apramycin has a bactericidal effect on Escherichia coli, Salmonella, Pseudomonas aeruginosa, Staphylococcus, Streptococcus, Proteus, Bordetella, some types of mycoplasmas (M. hyopheumoniae). Inactive against anaerobic microorganisms. The drug is characterized by good tolerance and low toxicity in all animal species. A unique feature of apramycin is the lack of risk of microflora resistance formation to this antibiotic: due to the specific chemical structure of the apramycin molecule, it is not inactivated by bacterial aminoglycoside-modifying enzymes (AGMP), which ensures high efficiency even in the case of multiple drug resistance of microflora. When administered orally, apramycin is practically not absorbed and creates selectively high therapeutic concentrations throughout the gastrointestinal tract. The therapeutic concentration of the antibiotic after a single oral administration is maintained for 24 hours. The drug was developed by Balkanpharm, approved for use by the Veterinary Department of the Ministry of Agriculture of the Russian Federation on October 3, 2000 (registration number PVI-2-4.0 / 00980).

Xanthan gum is a polysaccharide with long chain molecules consisting of glucose sugars, mannoxa and glucuronic acid. It has the ability to stabilize solutions (to keep particles in suspension) and good absorption and emulsifying properties.

A complex combination of these drugs is apramycin and xanthan gum, which is a polymer containing free functional groups, due to which apramycin is retained on the surface of polymer molecules. And since xanthan gum has a high absorption capacity, the therapeutic effect is multiplied and is local in nature.

Case Study

The studies were carried out at the dairy complex of the FSUE "Streletskoye" RAAS, located in the Oryol district of the Oryol region.

The identification of patients with mastitis in cows was carried out in accordance with the instruction “Instructions for the diagnosis, therapy and prevention of mastitis in cows” (2000). Subclinical mastitis was detected using a rapid mastitis test (BMT). Clinical mastitis was diagnosed visually by the nature of the secretion of the mammary gland. Bacteriological studies of milk samples from sick cows were isolated by agalactic streptococcus and Staphylococcus aureus.

For research, four groups of cows were selected, two of which (one with subclinical and the other with clinical mastitis) were treated with the well-known drug - dienomast, the other two groups of cows (with subclinical and clinical mastitis) - according to the proposed method.

The drugs were injected into all four lobes of the udder, regardless of their defeat. To the cows of the first group, the drug was injected into all four lobes of the udder, regardless of their defeat. In the second experimental group of cows, the drug was administered only in the affected lobes of the udder. Groups of cows 3 and 4 were treated according to the proposed method with a solution of ampramycin and xanthan gum. The drug was administered itcisternally in an amount of 10 ml in the composition: apromycin - 8.2%, xanthan gum 0.7% and distilled water - 91.1%. The drug was administered after the last evening milking of cows during start-up in the dry period once. Before the introduction of the drug, the secret was released from the affected portion of the udder of the cow and disposed of, the nipple was disinfected. In the cold season, the preparation was heated to 37 ° C before use, and it was thoroughly shaken until a uniform suspension was obtained. From the vial, the preparation was taken into a sterile syringe 10 ml. The nipple was disinfected with an alcohol swab. The syringe was tightly pressed to the outer opening of the nipple canal, the drug was injected into the nipple cistern of the udder by carefully pressing the syringe plunger. After the administration of the drug, a light massage of the nipple of the affected lobe of the udder was performed from the bottom up.

Based on the tests, the therapeutic effectiveness of the proposed method of treatment with the drug using apromycin and xanthan gum was established, both in the subclinical and clinical forms of mastitis in the dry period of cows. In bacteriological studies, it was found that inhibitory substances were not found in milk already on the second day after treatment of cows.

The results of treatment of cows with subclinical and clinical mastitis are shown in the table.

Results of treatment of cows with subclinical and clinical mastitis Treatment method Subclinical form of mastitis The clinical form of mastitis Treated Cured Percent Treated Cured Percent cows / cows / cured cows / cows / cured share share cows / share share cows / udder udder share udder udder share udder udder with the drug Dienomast 16/32 15/31 93.7 / 96.8 16/34 14/32 87 / 94.1 with the proposed drug 5/16 5/16 100/100 16/32 16/32 100/100

Using the proposed method for the treatment of mastitis in cows in the dry period allows:

- to provide higher therapeutic efficacy, with the simultaneous administration of the drug in all lobes of the udder (regardless of their affection);

- in comparison with imported drugs, reduce the amount of culled milk;

- reduce by 3-4 times the material costs for the treatment of mastitis in cows in the dry period in comparison with known drugs.

Thus, the method of treating mastitis in cows in the dry period using a preparation containing apromycin and xanthan gum allows to increase the therapeutic effect compared to known methods, in addition, it is 3-4 times cheaper than known imported drugs.

Claims (1)

A method of treating mastitis in cows in the dry period with the inclusion of an antimicrobial preparation, characterized in that apramycin in combination with xanthan gum is used as an antimicrobial preparation in ratios, wt.%: Apramycin - 5.0-10.0; xanthan gum - 0.25-1.0; distilled water - the rest is up to 100, moreover, the drug is administered itcisternally after the last evening milking before being transferred to the dry group in the amount of 10 ml once.